UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2020

 

(Commission File No. 001-39308)

 

 

 

CALLIDITAS THERAPEUTICS AB

(Translation of registrant’s name into English)

 

 

 

Kungsbron 1, C8
SE-111 22
Stockholm, Sweden
(Address of registrant’s principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. 

 

Form 20-F x    Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

  

Enclosed hereto is a copy of an announcement published by Calliditas Therapeutics AB on November 27, 2020.

 

The information contained in this Form 6-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

EXHIBIT INDEX

 

Exhibit   Description
99.1   Company announcement dated November 27, 2020

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CALLIDITAS THERAPEUTICS AB
       
Date: November 27, 2020 By: /s/ Fredrik Johansson  
    Fredrik Johansson  
    Chief Financial Officer  

 

 

Exhibit 99.1

 

 

Stockholm, Sweden November 27, 2020

 

Calliditas Therapeutics’ nomination committee for the AGM 2021

 

Calliditas Therapeutics AB (publ.) publishes the nomination committee’s composition for the AGM in 2021.

 

The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017, consists of:

 

• Patrick Sobocki, appointed by Stiftelsen Industrifonden

 

• Spike Loy, appointed by BVF

 

• Karl Tobieson, appointed by Linc AB

 

• Elmar Schnee (chairman of the board of directors)

 

The nomination committee shall, before the annual general meeting 2021, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, election of auditors, the determination of fees and matters pertaining thereto.

 

For more information please visit:

 

https://www.calliditas.se/en/nomination-committee-2314/

 

Shareholders who wish to submit proposals to the nomination committee for the annual general meeting on May 27, 2021 can do so by e-mail to finance@calliditas.com. Proposals should be submitted to the nomination committee before April 5, 2021.

 

For further information, please contact:

Fredrik Johansson, CFO at Calliditas

Email: fredrik.johansson@calliditas.com

Telephone: +46 703 52 91 90

 

The information was submitted for publication, through the agency of the contact person set out above, at 4.00 p.m on November 27, 2020.

 

About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.